Aptinyx to Present at Upcoming Virtual Investor Conferences
June 16, 2020 08:37 ET
|
Aptinyx Inc.
EVANSTON, Ill., June 16, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports First Quarter 2020 Financial Results and Highlights
May 14, 2020 16:03 ET
|
Aptinyx Inc.
Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations...
Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020
April 30, 2020 08:47 ET
|
Aptinyx Inc.
EVANSTON, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 30, 2020 16:01 ET
|
Aptinyx Inc.
Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common...
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
March 18, 2020 16:01 ET
|
Aptinyx Inc.
EVANSTON, Ill., March 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
February 27, 2020 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Zhittya Genesis Medicine Releases Latest White Paper Highlighting its Potential Breakthrough Drug Treatment for Chronic Depression
February 19, 2020 12:00 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya” or the “Company”), announced that its latest White Paper, which details results on its...
Aptinyx to Present at Upcoming Investor Conferences
February 19, 2020 08:37 ET
|
Aptinyx Inc.
EVANSTON, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease
January 30, 2020 07:07 ET
|
Aptinyx Inc.
EVANSTON, Ill., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
January 14, 2020 16:01 ET
|
Aptinyx Inc.
EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...